Generic Name and Formulations:
Ibutilide fumarate 0.1mg/mL; soln for IV infusion.
Indications for CORVERT:
Rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.
Give by IV infusion over 10 minutes. ≥18yrs: (≥60kg) initially 1mg; (<60kg) initially 0.01mg/kg. If no response, may repeat second 10-minute infusion of equal strength given 10 minutes after first infusion. Discontinue infusion as soon as the presenting arrhythmia has terminated, or if sustained/nonsustained ventricular tachycardia or marked QT prolongation occurs.
<18yrs: not recommended.
Risk of fatal arrhythmias (eg, sustained polymorphic ventricular tachycardia, usually associated with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation may occur. Be experienced with the treatment and monitoring of life-threatening arrhythmias before administering. Have cardiac monitoring equipment and proper medication available. Correct hypokalemia and hypomagnesemia before starting. Monitor ECG continuously for at least 4 hours post infusion or until QTC returned to baseline. Proarrhythmia conditions (eg, ventricular arrhythmias, atrial flutter or fibrillation, QTC intervals >440 msec, hypokalemia, history of CHF, low left ventricular ejection fraction). Previous polymorphic ventricular tachycardia: not recommended. Renal or hepatic dysfunction (monitor). Pregnancy (Cat.C). Nursing mothers: not recommended.
Class III antiarrhythmic.
Class Ia antiarrhythmics (eg, disopyramide, quinidine, procainamide) or other Class III drugs (eg, amiodarone, sotalol): do not give concomitantly or within 4 hours post-infusion. QT prolongation with phenothiazines, tricyclic and tetracyclic antidepressants, H1 receptor antagonists. Caution with digoxin.
Ventricular extrasystoles, sustained or nonsustained polymorphic ventricular tachycardia, sustained monomorphic ventricular tachycardia, headache, hypo- or hypertension, tachycardia, bundle branch block, AV block, nausea, QT segment prolonged, bradycardia.
Single-dose vial (10mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib